{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:16:14Z","timestamp":1786122974803,"version":"build-2736575974"},"reference-count":81,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006377","name":"Purdue University","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100006377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Indiana Clinical and Translational Science Institute","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Naturally occurring canine invasive urothelial carcinoma (InvUC) often harbors a BRAFV595E mutation, analogous to human BRAFV600E found across multiple cancer types, and has been used to investigate the effects of BRAF-targeted therapy. To investigate proteomic and phosphoproteomic changes during therapy, we analyzed 42 samples from 14 dogs with BRAFV595E-positive InvUC treated with vemurafenib. Tumors were collected via cystoscopy before treatment (Pre-Vem), 1 month into treatment (Vem-1-month), and at the time of progressive disease (Vem-PD). We observed consistent early suppression of proteins and phosphosites in tumors after 1 month of vemurafenib treatment in dogs that responded to the treatment, followed by their rebound at the time of progressive disease, highlighting early tumor suppressive events that are later reversed as tumors adapt and develop resistance. Key pathways affected included \"positive regulation of telomerase assembly and localization to Cajal body\", \"positive regulation of protein localization to telomere\", and \"positive regulation of protein localization to Cajal body\". Additionally, consistent \"Rho GTPase signaling\" changes were observed across both proteomic and phosphoproteomic analyses, underscoring the functional reactivation of this pathway in resistant tumors. In summary, these findings reveal molecular signatures of early response and acquired resistance to vemurafenib and offer a valuable resource for future investigation of BRAF-targeted therapy.<\/jats:p>","DOI":"10.1021\/acs.jproteome.6c00246","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:08:03Z","timestamp":1782464883000},"page":"4262-4275","source":"Crossref","is-referenced-by-count":0,"title":["Proteomic\nSignatures of Vemurafenib Resistance in\nCanine Urothelial Carcinoma Harboring the BRAFV595E Mutation"],"prefix":"10.1021","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-1291","authenticated-orcid":true,"given":"Rodrigo","family":"Mohallem","sequence":"first","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Dhawan","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Enstrom","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah W.","family":"Knapp","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]},{"name":"Purdue University Institute for Cancer Research , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-1536","authenticated-orcid":true,"given":"Uma K.","family":"Aryal","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2026080709084866700_cit1","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic\nbasis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer\nBiol."},{"issue":"7463","key":"2026080709084866700_cit2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures\nof mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"1","key":"2026080709084866700_cit3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1939-1676.2000.tb01492.x","article-title":"Companion\nAnimal Medicine in the Age of Medical Genetics","volume":"14","author":"Patterson","year":"2000","journal-title":"J. Vet. Int. Med."},{"issue":"12","key":"2026080709084866700_cit4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nrg1492","article-title":"Dog star\nrising: the canine genetic system","volume":"5","author":"Sutter","year":"2004","journal-title":"Nat. Rev.\nGenet."},{"issue":"6","key":"2026080709084866700_cit5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00335-007-9037-1","article-title":"Understanding hereditary diseases\nusing the dog and human as companion model systems","volume":"18","author":"Tsai","year":"2007","journal-title":"Mamm. Genome"},{"issue":"10","key":"2026080709084866700_cit6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000161","article-title":"The Comparative\nOncology\nTrials Consortium: Using Spontaneously Occurring Cancers in Dogs to\nInform the Cancer Drug Development Pathway","volume":"6","author":"Gordon","year":"2009","journal-title":"PLoS Med."},{"issue":"7069","key":"2026080709084866700_cit7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nature04338","article-title":"Genome\nsequence, comparative analysis and haplotype\nstructure of the domestic dog","volume":"438","author":"Lindblad-Toh","year":"2005","journal-title":"Nature"},{"issue":"1673","key":"2026080709084866700_cit8","doi-asserted-by":"publisher","first-page":"20140231","DOI":"10.1098\/rstb.2014.0231","article-title":"Comparative\noncology: what dogs and other species can teach us about\nhumans with cancer","volume":"370","author":"Schiffman","year":"2015","journal-title":"Philos. Trans. R. Soc. B\nBiol. Sci."},{"issue":"1673","key":"2026080709084866700_cit9","doi-asserted-by":"publisher","first-page":"20140233","DOI":"10.1098\/rstb.2014.0233","article-title":"Species differences\nin tumour responses\nto cancer chemotherapy","volume":"370","author":"Lawrence","year":"2015","journal-title":"Philos. Trans. R. Soc.\nB Biol. Sci."},{"issue":"6","key":"2026080709084866700_cit10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ejca.2004.01.003","article-title":"Integrating pharmacology\nand in vivo cancer models\nin preclinical and clinical drug development","volume":"40","author":"Peterson","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"2026080709084866700_cit11","first-page":"4227","article-title":"Clinical Predictive\nValue of the\nin Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical\nCancer Models","volume":"9","author":"Voskoglou-Nomikos","year":"2003","journal-title":"Clin. Cancer. Res."},{"issue":"12","key":"2026080709084866700_cit12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2174\/138945012803530152","volume":"13","author":"P. Langdon","year":"2012","journal-title":"Curr. Drug Targets."},{"issue":"12","key":"2026080709084866700_cit13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nrc1235","article-title":"Comparative biology of mouse versus\nhuman cells: modelling\nhuman cancer in mice","volume":"3","author":"Rangarajan","year":"2003","journal-title":"Nat. Rev. Cancer."},{"issue":"9","key":"2026080709084866700_cit14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrc2192","article-title":"Maximizing mouse\ncancer models","volume":"7","author":"Frese","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"2026080709084866700_cit15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving human\ncancer therapy through the evaluation\nof pet dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat. Rev. Cancer."},{"issue":"1","key":"2026080709084866700_cit16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/vco.12740","article-title":"Characterizing the molecular and immune landscape of\ncanine bladder cancer","volume":"20","author":"Cronise","year":"2022","journal-title":"Vet. Comp. Oncol."},{"issue":"7","key":"2026080709084866700_cit17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nrc2877","article-title":"Non-germline genetically\nengineered mouse models for translational cancer research","volume":"10","author":"Heyer","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"2026080709084866700_cit18","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3389\/fonc.2019.01493","article-title":"Naturally-Occurring Invasive Urothelial\nCarcinoma in\nDogs, a Unique Model to Drive Advances in Managing Muscle Invasive\nBladder Cancer in Humans","volume":"9","author":"Knapp","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"2026080709084866700_cit19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10577-015-9471-y","article-title":"Canine\nurothelial carcinoma: genomically aberrant and comparatively relevant","volume":"23","author":"Shapiro","year":"2015","journal-title":"Chromosome Res."},{"issue":"8","key":"2026080709084866700_cit20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007571","article-title":"Naturally-occurring\ncanine invasive urothelial carcinoma harbors luminal and basal transcriptional\nsubtypes found in human muscle invasive bladder cancer","volume":"14","author":"Dhawan","year":"2018","journal-title":"PLoS Genet."},{"issue":"3","key":"2026080709084866700_cit21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder\nCancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"6","key":"2026080709084866700_cit22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1541-7786.MCR-14-0689","article-title":"Homologous\nMutation to Human BRAF V600E Is\nCommon in Naturally Occurring Canine Bladder Cancer\u2500Evidence\nfor a Relevant Model System and Urine-Based Diagnostic Test","volume":"13","author":"Decker","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"12","key":"2026080709084866700_cit23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144170","article-title":"Detection\nof BRAF Mutation in Urine\nDNA as a Molecular Diagnostic for Canine Urothelial and Prostatic\nCarcinoma","volume":"10","author":"Mochizuki","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2026080709084866700_cit24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.eururo.2016.07.049","article-title":"Targeted\nExome Sequencing of the Cancer Genome in Patients\nwith Very High-risk Bladder Cancer","volume":"70","author":"Longo","year":"2016","journal-title":"Eur. Urol."},{"issue":"3","key":"2026080709084866700_cit25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0168-9525(99)01958-7","article-title":"Canine genetics comes of age","volume":"16","author":"Ostrander","year":"2000","journal-title":"Trends Genet."},{"issue":"11","key":"2026080709084866700_cit26","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1158\/1535-7163.MCT-20-0893","article-title":"Phase I\/II Trial of Vemurafenib in Dogs with Naturally Occurring,\nBRAF-mutated Urothelial Carcinoma","volume":"20","author":"Rossman","year":"2021","journal-title":"Mol. Cancer\nTher."},{"issue":"1","key":"2026080709084866700_cit27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and\nMEK inhibitors for melanoma: latest\nevidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther. Adv. Med.\nOncol."},{"issue":"7074","key":"2026080709084866700_cit28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"issue":"9","key":"2026080709084866700_cit29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition\nof Mutated, Activated BRAF in Metastatic\nMelanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"2026080709084866700_cit30","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-13-0661","article-title":"Identification\nof Multiple Mechanisms of Resistance\nto Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma\nSuccessfully Rechallenged after Progression","volume":"19","author":"Romano","year":"2013","journal-title":"Clin. Cancer. Res."},{"issue":"6","key":"2026080709084866700_cit31","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/cancers12061661","article-title":"BRAF Mutant\nMelanoma Adjusts to BRAF\/MEK Inhibitors\nvia Dependence on Increased Antioxidant SOD2 and Increased Reactive\nOxygen Species Levels","volume":"12","author":"Yuan","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026080709084866700_cit32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/cancers12020482","article-title":"Current\nAdvances in the Treatment\nof BRAF-Mutant Melanoma","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"2026080709084866700_cit33","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma\nantigen expression and a more favorable tumor microenvironment in\npatients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer\nRes."},{"issue":"8","key":"2026080709084866700_cit34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted\nagents\nand immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin Oncol"},{"issue":"8","key":"2026080709084866700_cit35","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/cancers12082104","article-title":"Novel Targeted\nTherapies for Metastatic Thyroid Cancer\u2500A Comprehensive Review","volume":"12","author":"Al-Jundi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026080709084866700_cit36","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/cancers12051168","article-title":"Recent Advances\nin Targeted Therapies for Advanced Gastrointestinal Malignancies","volume":"12","author":"C. Huynh","year":"2020","journal-title":"Cancers"},{"key":"2026080709084866700_cit37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","article-title":"Immunomodulatory effects of BRAF\nand MEK inhibitors: Implications for Melanoma therapy","volume":"136","author":"Kuske","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"6","key":"2026080709084866700_cit38","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune\nEvolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"issue":"10","key":"2026080709084866700_cit39","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41416-018-0296-2","article-title":"Combinations of BRAF\ninhibitor and anti-PD-1\/PD-L1\nantibody improve survival and tumour immunity in an immunocompetent\nmodel of orthotopic murine anaplastic thyroid cancer","volume":"119","author":"Gunda","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"7","key":"2026080709084866700_cit40","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/cells11071172","article-title":"Multi-Omics Approach\nReveals Dysregulation of Protein\nPhosphorylation Correlated with Lipid Metabolism in Mouse Non-Alcoholic\nFatty Liver","volume":"11","author":"Kim","year":"2022","journal-title":"Cells"},{"key":"2026080709084866700_cit41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2020.104072","article-title":"Proteome\nand phosphoproteome characterization\nof liver in the postprandial state from diet-induced obese and lean\nmice","volume":"232","author":"Zembroski","year":"2021","journal-title":"J. Proteomics"},{"issue":"12","key":"2026080709084866700_cit42","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high\npeptide identification rates, individualized\np.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"2026080709084866700_cit43","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","article-title":"Accurate proteome-wide\nlabel-free quantification by delayed normalization\nand maximal peptide ratio extraction, termed MaxLFQ","volume":"13","author":"Cox","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"issue":"11","key":"2026080709084866700_cit44","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1021\/acs.jproteome.8b00170","article-title":"Analysis of Protein\nComplexes in the Unicellular Cyanobacterium\nCyanothece ATCC 51142","volume":"17","author":"Aryal","year":"2018","journal-title":"J. Proteome Res."},{"issue":"9","key":"2026080709084866700_cit45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The Perseus\ncomputational platform for comprehensive analysis of (prote) omics\ndata","volume":"13","author":"Tyanova","year":"2016","journal-title":"Nat. Methods"},{"issue":"1","key":"2026080709084866700_cit46","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides\na biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"issue":"8","key":"2026080709084866700_cit47","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","article-title":"ShinyGO: a graphical\ngene-set enrichment\ntool for animals and plants","volume":"36","author":"Ge","year":"2020","journal-title":"Bioinformatics"},{"issue":"2","key":"2026080709084866700_cit48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours:\nRevised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur.\nJ. Cancer"},{"issue":"Suppl_1","key":"2026080709084866700_cit49","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1093\/carcin\/bgv037","article-title":"Metabolic reprogramming and dysregulated metabolism:\ncause, consequence and\/or enabler of environmental carcinogenesis?","volume":"36","author":"Robey","year":"2015","journal-title":"Carcinogenesis"},{"issue":"6","key":"2026080709084866700_cit50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/sj.onc.1200886","article-title":"PCNA: structure,\nfunctions and interactions","volume":"14","author":"Kelman","year":"1997","journal-title":"Oncogene"},{"issue":"1","key":"2026080709084866700_cit51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12967-024-04964-8","article-title":"RBBP7, regulated by\nSP1, enhances the Warburg effect to facilitate the proliferation of\nhepatocellular carcinoma cells via PI3K\/AKT signaling","volume":"22","author":"Fang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"5","key":"2026080709084866700_cit52","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3892\/or.2017.5982","article-title":"SSRP1 silencing\ninhibits the proliferation and malignancy of human glioma cells via\nthe MAPK signaling pathway","volume":"38","author":"Liao","year":"2017","journal-title":"Oncol. Rep."},{"issue":"5","key":"2026080709084866700_cit53","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/cbin.11740","article-title":"Research progress\nof Bub3 gene in malignant tumors","volume":"46","author":"Wang","year":"2022","journal-title":"Cell Biol.\nInt."},{"issue":"5","key":"2026080709084866700_cit54","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/ph15050544","article-title":"Adenosine\nconjugated docetaxel nanoparticles\u2500proof of concept studies\nfor non-small cell lung cancer","volume":"15","author":"Aldawsari","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2026080709084866700_cit55","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104816","article-title":"DYNLRB1 is\nessential for dynein mediated transport\nand neuronal survival","volume":"140","author":"Terenzio","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"2026080709084866700_cit56","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fonc.2019.00491","article-title":"DYNC1I1\npromotes the proliferation\nand migration of gastric cancer by up-regulating IL-6 expression","volume":"9","author":"Gong","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"2026080709084866700_cit57","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.cell.2014.10.059","article-title":"Proteostatic\ncontrol of telomerase\nfunction through TRiC-mediated folding of TCAB1","volume":"159","author":"Freund","year":"2014","journal-title":"Cell"},{"issue":"1","key":"2026080709084866700_cit58","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1038\/ncomms10966","article-title":"Cajal bodies are linked to genome\nconformation","volume":"7","author":"Wang","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"2026080709084866700_cit59","doi-asserted-by":"publisher","first-page":"2256036","DOI":"10.1080\/19491034.2023.2256036","article-title":"Coilin and\nCajal bodies","volume":"14","author":"Stanek","year":"2023","journal-title":"Nucleus"},{"issue":"1","key":"2026080709084866700_cit60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13578-015-0051-9","article-title":"The function, regulation\nand therapeutic implications\nof the tumor suppressor protein, PML","volume":"5","author":"Guan","year":"2015","journal-title":"Cell &\nBiosci."},{"issue":"2","key":"2026080709084866700_cit61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(02)00626-8","article-title":"The role of PML in tumor suppression","volume":"108","author":"Salomoni","year":"2002","journal-title":"Cell"},{"issue":"17","key":"2026080709084866700_cit62","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.3390\/molecules25173935","article-title":"Fatty Acid Synthase: An Emerging\nTarget in Cancer","volume":"25","author":"Fhu","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"2026080709084866700_cit63","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase\nand the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"2026080709084866700_cit64","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3389\/fonc.2019.01493","article-title":"Naturally-Occurring Invasive Urothelial\nCarcinoma in\nDogs, a Unique Model to Drive Advances in Managing Muscle Invasive\nBladder Cancer in Humans","volume":"9","author":"Knapp","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"2026080709084866700_cit65","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-12-2101","article-title":"Targeting folate receptors to treat invasive\nurinary bladder cancer","volume":"73","author":"Dhawan","year":"2013","journal-title":"Cancer Res."},{"key":"2026080709084866700_cit66","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.920957","article-title":"A Review of the Molecular\nPathways Involved in Resistance to BRAF\nInhibitors in Patients with Advanced-Stage Melanoma","volume":"26","author":"Tian","year":"2020","journal-title":"Med. Sci. Monit."},{"issue":"21","key":"2026080709084866700_cit67","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2013.52.1377","article-title":"Combining targeted\ntherapy with immunotherapy in BRAF-mutant melanoma: promise and challenges","volume":"32","author":"Hu-Lieskovan","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"2026080709084866700_cit68","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/cancers11101480","article-title":"Epigenetic\nMechanisms of Escape from BRAF Oncogene\nDependency","volume":"11","author":"Khaliq","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026080709084866700_cit69","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/pharmaceutics14051084","article-title":"BUB3, beyond the Simple\nRole of Partner","volume":"14","author":"Silva","year":"2022","journal-title":"Pharmaceutics"},{"issue":"15","key":"2026080709084866700_cit70","doi-asserted-by":"publisher","first-page":"11205","DOI":"10.1074\/jbc.M611279200","article-title":"The DYNLT3\nLight Chain Directly Links\nCytoplasmic Dynein to a Spindle Checkpoint Protein, Bub3*","volume":"282","author":"Lo","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"5","key":"2026080709084866700_cit71","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/cancers12051179","article-title":"Dysregulation\nof Rho GTPases in Human Cancers","volume":"12","author":"Jung","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2026080709084866700_cit72","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/cells8091037","article-title":"Regulation\nof Rho GTPases by RhoGDIs in Human Cancers","volume":"8","author":"Cho","year":"2019","journal-title":"Cells"},{"key":"2026080709084866700_cit73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2022.104808","article-title":"Integrated proteomic\nand phosphoproteomic analysis for characterization\nof colorectal cancer","volume":"274","author":"Zhu","year":"2023","journal-title":"J. Proteomics"},{"issue":"7","key":"2026080709084866700_cit74","doi-asserted-by":"publisher","first-page":"2410142","DOI":"10.1002\/advs.202410142","article-title":"Multidimensional Proteomic Landscape Reveals\nDistinct\nActivated Pathways Between Human Brain Tumors","volume":"12","author":"Yang","year":"2025","journal-title":"Adv. Sci."},{"key":"2026080709084866700_cit75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2024.105260","article-title":"Proteomic\nand Phosphoproteomic analysis of thyroid papillary carcinoma: Identification\nof potential biomarkers for metastasis","volume":"306","author":"Peng","year":"2024","journal-title":"J. Proteomics"},{"issue":"10","key":"2026080709084866700_cit76","doi-asserted-by":"publisher","first-page":"114774","DOI":"10.1016\/j.celrep.2024.114774","article-title":"Phosphoproteomic\nsubtyping of gastric cancer reveals\ndynamic transformation with chemotherapy and guides targeted cancer\ntreatment","volume":"43","author":"Shoji","year":"2024","journal-title":"Cell Rep."},{"issue":"1","key":"2026080709084866700_cit77","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity\nof triple negative\nbreast cancer: Current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"2026080709084866700_cit78","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1021\/acs.chemrestox.3c00223","article-title":"Recent Contributions of Mass Spectrometry-Based\n\u201cOmics\u201d\nin the Studies of Breast Cancer","volume":"37","author":"Banerjee","year":"2024","journal-title":"Chem. Res.\nToxicol."},{"issue":"47","key":"2026080709084866700_cit79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2413837121","article-title":"Parallel phosphoproteomics\nand metabolomics map the global metabolic tyrosine phosphoproteome","volume":"121","author":"Hillis","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"2026080709084866700_cit80","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2024.100819","article-title":"Molecular\nSignatures of Neurodegenerative\nDiseases Identified by Proteomic and Phosphoproteomic Analyses in\nAging Mouse Brain","volume":"23","author":"Mohallem","year":"2024","journal-title":"Mol. Cell. Proteom."},{"issue":"D1","key":"2026080709084866700_cit81","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022:\na hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res."}],"container-title":["Journal of Proteome Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jproteome.6c00246","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jprobs\/article-pdf\/25\/8\/4262\/65247193\/acs.jproteome.6c00246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jprobs\/article-pdf\/25\/8\/4262\/65247193\/acs.jproteome.6c00246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:15:12Z","timestamp":1786108512000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jprobs\/article\/25\/8\/4262\/5169441\/Proteomic-Signatures-of-Vemurafenib-Resistance-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,8,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jproteome.6c00246","relation":{},"ISSN":["1535-3893","1535-3907"],"issn-type":[{"value":"1535-3893","type":"print"},{"value":"1535-3907","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}